Artivion (NYSE:AORT) Posts Earnings Results, Misses Expectations By $0.51 EPS

Artivion (NYSE:AORT) announced its earnings results on Monday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51), reports. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The company had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. Artivion updated its FY 2025 guidance to EPS.

Artivion Stock Performance

Shares of NYSE AORT opened at $25.33 on Wednesday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion has a 12-month low of $18.38 and a 12-month high of $32.33. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -1,266.25 and a beta of 1.75. The firm has a 50 day moving average of $29.75 and a 200 day moving average of $27.83.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 8,070 shares of Artivion stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the transaction, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at $4,634,323.44. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Amy Horton sold 4,329 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the sale, the chief accounting officer now directly owns 135,660 shares of the company’s stock, valued at $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,017 shares of company stock worth $600,007. Company insiders own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

AORT has been the subject of a number of recent research reports. JMP Securities reissued a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC dropped their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday. Oppenheimer lifted their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Finally, Stifel Nicolaus reduced their target price on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.